Formnext Germany

More Efficient Drug Screening with 3D Bioprinting

Share this Article

Taking a drug to market is a competitive, costly and challenging process involving preclinical laboratory and animal testing before the even more time-consuming and expensive four phases of human clinical trials, which can take as many as 7 to 15 years at price tags as high as $5.5 billion. Even if 10 viable drug compounds are identified for human trials, only 1 out of 9 will actually make it to market. Given this high attrition rate, can bioprinting save valuable time and resources by better identifying viable compounds in order to move only the most promising drugs to clinical trials?

The limitations of animal testing

During the initial stages of drug discovery, often referred to as preclinical trials, new chemical entities (NCEs) are monitored to determine the life cycle of the compounds inside and outside of the targeted system (pharmacokinetics) and their chemical reactions (metabolism). Because of the ethical issues surrounding human trials and their high costs, a significant number of these early tests are performed on animals.

While the transition from preclinical animal testing to clinical human trials has improved thanks to better research tools and the rise of artificial intelligence in target identification, there is still a real need for improved preclinical screening because animal testing often fails to recapitulate the complexity of the human metabolism, leading to false positives and negatives that do not accurately reflect the toxicity of drugs to human systems.

3D cell cultures are more relevant

Given the limitations of animal models, it is no wonder that scientists have turned to human organ models. But although human cells have long been cultured in 2D, in recent years, a paradigm shift has led more and more scientists to recognize the importance of working with human cells in the 3D environments afforded by bioprinting in order to produce more physiologically relevant models. Combining the automation of cell culturing in 3D bioprinting with carefully tailored biomaterials, known as bioinks, has made it possible to grow, feed and maintain human organ models in larger quantities and in a lot less time, reducing time and labor spent on these tasks. Laboratory robotics can also now pick and place cell culture reagents or other NCEs and liquid samples in high numbers, enabling higher throughput screening and running a variety of other laboratory tasks more efficiently.

Bioinks better mimic ECM

Bioinks are another powerful tool that help researchers advance their drug discovery research. Tissue-specific bioinks improve cell adhesion and differentiation, helping with the formation of human organoids. Proteins and other biological factors can also be added to more accurately recreate extracellular matrices (ECM), once again better simulating the in vivo microenvironments. Furthermore, with multiple methods of crosslinking (chemical, light, thermal), the stiffness of constructs can be modulated to better serve specific cell types, like cartilage or bone tissue.

Learn more

Bioprinting’s more relevant human organ models can save the drug industry time and money by more efficiently identifying viable compounds in the initial stages of drug development in order to move only the most promising compounds to costly human clinical trials. The technology’s growing influence means that scientists continue to validate more and more applications. Dive deeper into how the bioprinting industry is changing drug screening and development. Watch our webinar on 3D bioprinting for COVID-19 studies or read our application note, which discusses the effectiveness of testing drug efficacy in 2D and 3D.



Share this Article


Recent News

UT Austin Taps Electroninks as Materials Supplier for DARPA AMME Program

From Rapid Qualification to On-ship 3D Printing, ABS Sets New Standards in Maritime AM



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

3D Systems Helps NASA, Penn State, and ASU Take the Heat Off Space Missions

As space missions get more ambitious, keeping equipment safe from extreme heat and cold is becoming a big challenge. That’s where 3D printing steps in, and 3D Systems (NYSE: DDD)...

Featured

Additive Manufacturing in the Small Arms Silencers Market – Eight Years Later

In 2017, AM Research (then known as SmarTech Publishing) published what probably seemed like an odd research note to the AM industry at the time – an opportunity brief and opinion...

Nikon Advanced Manufacturing & America Makes to Develop Aluminum Powder Dataset

Nikon Advanced Manufacturing Inc. (NAMI), the Long Beach-based end-to-end metal additive manufacturing (AM) firm, has announced that the company is partnering with the Manufacturing USA Institute America Makes to develop...

Metal Powder Supplier Elementum 3D Added to $46B Air Force Contract

Elementum 3D, a Colorado-based developer and supplier of metal powders used in additive manufacturing (AM), announced that the company has been added to the vendors list in the fourth on-ramp...